Reaction
Mediastinitis reporting signals
As of the last recalculation, Mediastinitis appears in 574 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 87.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 27 | 87.3 | 87.5 |
| Voriconazole Injection | 33 | 58.4 | 58.5 |
| Daptomycin | 12 | 48.2 | 48.2 |
| Voriconazole | 33 | 41.7 | 41.8 |
| Micafungin Sodium | 9 | 39.1 | 39.1 |
| Amphotericin B | 13 | 38.5 | 38.5 |
| Meropenem | 30 | 35.7 | 35.7 |
| Cefepime | 12 | 31.0 | 31.0 |
| Cefepime Hydrochloride | 12 | 27.6 | 27.6 |
| Valganciclovir Hydrochloride Powder, | 9 | 27.2 | 27.2 |
| Mycophenilic Acid | 15 | 26.9 | 26.9 |
| Posaconazole Delayed-Release | 8 | 26.8 | 26.8 |
| Tacrolimus Ointment 0.1% | 78 | 26.1 | 26.1 |
| Tacrolimus Extended-Release Capsules | 78 | 26.1 | 26.1 |
| Linezolid | 18 | 22.6 | 22.6 |
| Fondaparinux Sodium | 5 | 22.6 | 22.6 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 14.5 | 14.5 |
| Pemetrexed | 8 | 13.7 | 13.7 |